Skip to main content
NIH funding notice RFA-DA-22-012

Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)

Closed on August 5, 2021.

Posted
May 24, 2021
Close date
August 5, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,584,834 in first-year total cost, median $792,417.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 SXC-G (09)]2

Most frequent institutions

  1. FATHER FLANAGAN'S BOYS' HOME1
  2. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
Competing awards under RFA-DA-22-012 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV1R01DA056058-01ELLIS, RONALD J.UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$896,116ZDA1
2022Suppression of Pathological Spontaneous Cortical Dynamics and Inflammation in NeuroHIV1R01DA056223-01WILSON, TONY WFATHER FLANAGAN'S BOYS' HOME, NE$688,718ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-22-012: Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional) | ScienceDex | ConductScience